Sustainability & Climate

New Phase 2a data reveals Oruka Therapeutics' ORKA-001 achieved complete skin clearance in nearly two-thirds of patients, positioning it as a potential game-changer.

The Sterling Group's acquisition of The Scruggs Companies signals a major private equity push into America's vital and aging water infrastructure sector.

Diagnostics firm QuantiPath adds Roger Schaller, a veteran of high-profile exits, to its board, signaling a strategic push for its advanced food safety tech.

3E is offering a financial guarantee for its safety data, a first for the industry that could force competitors to prove their own data quality.

A new partnership brings a single-dose treatment for common, serious infections to Sub-Saharan Africa, a region with high prevalence and unmet medical needs.

With diesel prices soaring, new data reveals how fleets can reclaim thousands per vehicle by tackling 'invisible' fuel drains like idling and poor routing.

The firm's oversubscribed fund highlights investor confidence in its strategy of backing founder-owned industrial and services companies.

Simply Contact is using AI simulations to train agents for complex multilingual support, slashing onboarding time and fighting costly industry burnout.

Milwaukee's Zurn Elkay named a top US Climate Leader again, proving that deep cuts in emissions can fuel business success and solve real-world water issues.

A new long-term deal for the INTERCEPT system highlights a critical shift towards proactive pathogen reduction to protect France's blood supply from global threats.

With a $47M Series A, Fathom Therapeutics is using quantum physics and AI to simulate protein dynamics, aiming to create drugs for impossible targets.

Natural Fiber Welding debuts PLIANT™ PCS, a 100% biobased outsole that matches synthetic performance, aiming to end the footwear industry's reliance on plastic.

Swiss medtech vVARDIS secures a major Apollo investment, valuing it over $1B for its revolutionary non-invasive cavity treatment, Curodont™.

VSCP's appointment of Kurt Hilzinger signals a strategic push to leverage deep operational expertise in the competitive healthcare private equity market.

A major trial shows once-weekly rezafungin is as effective as daily drugs for preventing deadly fungal infections, heralding a new era for patient care.

Materials innovator Avient Corporation names 15-year veteran Joe Di Salvo as its new CFO, a move signaling strategic continuity and stability.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

In a key human trial, Sona Nanotech's heat-based therapy saw a 60% complete response in tumors for melanoma patients who had exhausted other options.

The company's SEAL™ device, targeting complex wide-neck aneurysms, completes its final submission, backed by a major US clinical trial.

For its fifth 'Off the Grid' campaign, L.L.Bean is pausing social media and introducing an 'Analog Tote,' betting that disconnecting is key to wellness.